Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial - Takeaways - MDSpire

Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial

  • By

  • Thierry Lebret

  • Xavier Paoletti

  • Geraldine Pignot

  • Mathieu Roumiguié

  • Marc Colombel

  • Laurent Savareux

  • Grégory Verhoest

  • Laurent Guy

  • Jérome Rigaud

  • Stéphane De Vergie

  • Grégoire Poinas

  • Stéphane Droupy

  • François Kleinclauss

  • Monique Courtade-Saïdi

  • Eric Piaton

  • Camelia Radulescu

  • Nathalie Rioux-Leclercq

  • Christine Kandel-Aznar

  • Karine Renaudin

  • Béatrix Cochand-Priollet

  • Yves Allory

  • Sébastien Nivet

  • Morgan Rouprêt

  • July 22, 2023

  • 0 min

Share

  • 1

    The VISIOCYT1 trial evaluated the VisioCyt® device for diagnosing bladder cancer using AI-based analysis of urothelial cell morphology.

  • 2

    VisioCyt® offers a noninvasive alternative to traditional cytology and cystoscopy, analyzing urine samples for tumor cell detection.

  • 3

    The trial included patients over 18 with suspected bladder cancer, assessing both positive and negative cytology and cystoscopy results.

  • 4

    Urine samples were prepared for both routine cytology and VisioCyt® testing, with strict criteria for evaluability based on urothelial cell count.

  • 5

    The primary objective of the validation phase was to assess the sensitivity of the VisioCyt® test compared to standard histopathological assessments.

Original Source(s)

Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial

  • by Thierry Lebret, Xavier Paoletti, Geraldine Pignot, Mathieu Roumiguié, Marc Colombel, Laurent Savareux, Grégory Verhoest, Laurent Guy, Jérome Rigaud, Stéphane De Vergie, Grégoire Poinas, Stéphane Droupy, François Kleinclauss, Monique Courtade-Saïdi, Eric Piaton, Camelia Radulescu, Nathalie Rioux-Leclercq, Christine Kandel-Aznar, Karine Renaudin, Béatrix Cochand-Priollet, Yves Allory, Sébastien Nivet, Morgan Rouprêt

  • July 22, 2023

Related Content

Miniaturised ultrasound evaluation at the bedside

PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions

Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study